Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria

Phase 2positiveCUE-221Positive

AI Analysis

Summary

Cue Biopharma announced positive topline results from a Phase 2 study of CUE-221 in chronic spontaneous urticaria, supporting advancement to Phase 2b/3 registration enabling study. The results suggest potential for differentiated clinical impact in patients with chronic hives.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Positive topline results from Phase 2 study; advancement to Phase 2b/3 registration enabling study planned

Importance:7/10

Sentiment:

0.85

Phase 2 datapositive resultschronic spontaneous urticariaadvancement to Phase 2b/3

Related Companies

$IBO

Read the original article

Published by GlobeNewswire Clinical Studies on September 20, 2026 10:00 AM

Read Original